Despite the fact that the statistics highlighting the natural history of peripheral artery disease (PAD) have been commonly understood for nearly a decade, its prevalence continues to increase at an alarming pace worldwide. Large-scale studies indicate that there will be 22 million patients with PAD by 2030. PAD exerts a deleterious effect on patient morbidity and mortality, with a threefold increase in the risk of cardiovascular death compared to patients without PAD.1-3 Advancing age, male sex, African American race/ethnicity, tobacco abuse, diabetes, dyslipidemia, hypertension, and coronary artery disease are all strongly associated with an increase in the risk of developing PAD. These patients present with a wide variety of symptoms, but only 10% to 20% have typical claudication symptoms, and almost 50% have asymptomatic PAD.4,5 These difficulties have hindered our ability to diagnose PAD and have led to low or delayed detection rates by health care providers,5 unfortunately leading many of these patients (< 10%) to only be discovered when they present with critical limb ischemia (CLI).6

NATURAL HISTORY OF CLI

The path that leads to the development of CLI is not governed by an organized progression through a series of clinical stages, as patients with PAD can be symptomatic or asymptomatic prior to reaching this terminal stage.7 Patients with CLI have a significantly increased risk for myocardial infarction, stroke, limb loss, and death. Within the first year of clinical diagnosis, an estimated 30% of patients with CLI will undergo a major amputation, and 25% to 30% will die.8 When revascularized, these patients require intensive care, complex procedures, surveillance, and the participation of a multidisciplinary team, utilizing resources that could be portrayed as an added strain to a health care system that is already under pressure.9 It should be emphasized that amputations are neither the solution nor the final step for patients with CLI. Instead, the initial amputation is followed by revisions, more proximal amputations, contralateral amputations, and cardiovascular procedures, all of which add to the total economic burden.

CLI THERAPIES

The treatment of CLI in the United States has been characterized as a pathway to amputation, as 67% of Medicare patients who underwent a major amputation did not have any other exploratory or therapeutic procedures prior to losing their limb.10 This finding was confirmed in a recent study of 20,464 Medicare patients with CLI who underwent amputations, which revealed that 71% had no revascularization and 54% did not even undergo angiography, underscoring the fact that revascularization procedures (endovascular and surgical) have largely been underutilized.11 This could be ascribed, at least in part, to the paucity of randomized controlled trials (RCTs) comparing both strategies, which have been difficult to implement.12 This represents a clear example of the existing gap between “real-world CLI practices” and the availability of evidence-based therapies. Over the last few years, there has been a significant increase in the amount of CLI-related data. However, these data continue to be applied mainly in the relatively few CLI centers of excellence, perpetuating the mismatch between data availability and day-to-day CLI practices.

Femoropopliteal Segment

Atherosclerotic plaque in CLI is omnipresent; however, approximately 65% of the obstructive lesions are located in the femoropopliteal space and exhibit complex features (length and degree of calcification) that qualify most of them as TASC C or D lesions. Endovascular techniques have continued to evolve and have slowly and progressively replaced the once ubiquitous surgical bypass, which remains relevant in cases with extensive femoral artery disease, particularly if there is involvement of the common femoral artery with extension into the deep femoral artery.

The most current randomized trial comparing infrainguinal saphenous vein bypass to both above-knee and below-knee segments with percutaneous transluminal angioplasty (PTA) is the BASIL trial.13 It found that endovascular therapy equaled the results achieved with surgery based on amputation-free survival at 6 months. Endovascular therapy was a less morbid procedure with equivalent quality of life outcomes and was significantly less expensive than surgery. There has been a widespread adoption of the endovascular-first approach since this trial, along with continuous innovations in endovascular techniques and devices.6 It is worth mentioning that at the time the BASIL results were published, the angioplasty group did not include stents or other adjunctive procedures; therefore, the study may not be reflective of current, more effective endovascular strategies. In a meta-analysis of observational studies from 1995 to 2012, no differences were found between endovascular and open surgical revascularization regarding all-cause mortality, amputation, or amputation-free survival at 2 years.14

Multiple studies have compared nitinol stents (both bare and covered) with PTA in the superficial femoral artery (SFA), without evidence of advantages of using covered over bare-metal stents (BMS) for the treatment of long and complex (TASC II C/D) SFA lesions.15 Prospective multicenter studies have shown improved patency for BMS when compared to PTA for the treatment of intermediate lesions (7 cm) in the SFA, with benefits sustained even after 3 years.16,17 Studies looking at interwoven nitinol stents report high patency rates in the treatment of long complex lesions.18 Adjunctive modalities such as atherectomy have also been studied as primary therapies. Orbital,19 laser,20 rotational/aspirational,21 and directional22,23 atherectomy devices have been evaluated, with promising results; however, concerns regarding the risk of distal embolization, restenosis, and perforations remain. More recently, 2-year data have emerged for the use of paclitaxel-coated, self-expanding nitinol stents (PCSES), revealing that this strategy remains superior to standard PTA,24 and earlier this year, the 5-year data comparing PCSES and PTA were published, showing that for lesions 65 ± 40 mm in length, PCSES offer better patency rates (66.4%) and freedom from target lesion revascularization (TLR; 84.9%) than standard PTA.25 However, the SFA presents significant challenges in achieving long-term results after endovascular intervention, secondary to the unique forces to which it is subjected.

Proximal continuity with the common femoral artery and distal continuity with the popliteal artery exposes the SFA to elongation with ambulation. Due to its superficial course and intimate interaction with the surrounding musculature, the SFA is subject to compressive and torsional forces. This can result in metal fatigue and stent fracture, which has been associated with restenosis, especially with first-generation stents. In addition, the SFA responds to stent implantation with a more potent inflammatory response than other vessels due to micromovements of the stent alongside the vessel wall, which lead to activation of the endothelium and inflammation. When stent segments overlap (often done while treating long SFA lesions), hinge points are created, potentiating the likelihood of stent fracture.

These limitations illustrate that although stent-related data for the SFA have improved, there is still a need to improve outcomes, which has led to the development of drug-coated balloons (DCBs). Results of the first large, international, prospective, multicenter RCT of DCBs versus bare PTA for the treatment of SFA disease (IN.PACT SFA) were published and demonstrated a significant advantage of DCB use when patency (82.2% vs 52.4%) and TLR (2.4% vs 20.6%) were analyzed.26 More recently, results of the LEVANT-2 study were released, showing a superior 12-month primary patency rate of 65.2% compared to PTA (52.6%), with a safety profile that was noninferior to the standard balloon.27 The latest study of the use of the In.Pact Admiral DCB (Medtronic) in this segment showed excellent 1-year results (83.2% primary patency) in long lesions (251.7 ± 78.9 cm) with moderate-to-severe calcification (50.4%) and 49.5% of total occlusions in a population mainly composed of claudicants (89.5%). Of note, only 10.5% of patients had CLI and, of those, only 1.6% were Rutherford class 5 and no patients were Rutherford class 6.28 Further studies are necessary to determine the role (if any) of combination therapies.

Infrapopliteal Segment

Revascularization of infrapopliteal (IP) disease is almost exclusively utilized for patients with CLI, as it is considered that most other clinical scenarios would not justify the risk of a tibial intervention. In this respect, the Society for Cardiovascular Angiography and Interventions published the first expert consensus document on the management of IP arterial disease. Assuming that the inflow vessels are patent and the femoropopliteal segment does not exhibit a hemodynamically significant stenosis, single-vessel tibial disease with patency of the other tibial arteries would not be expected to result in severe limb symptoms prompting the need for revascularization (unless the severely diseased tibial is the tibioperoneal trunk, which would represent a two-vessel disease equivalent).29

Recent efforts to standardize strategies for the management of IP disease have been brought to the forefront by the creation of a supplement to the latest version of the TASC II classification, addressing for the first time the different IP clinical/anatomical scenarios and their potential combinations.6 There is an extensive amount of literature pertaining to the surgical treatment of IP disease, primarily using the greater saphenous vein or other autologous veins as conduit material. The use of spliced grafts, allograft material, or prosthetic material such as polytetrafluoroethylene is less than ideal for this segment. One-year survival and limb salvage rates of 76% to 90% and 66% to 100%, respectively, have been reported.30-33 Major morbidity related to surgical bypass for IP disease and CLI is clinically important. Although the BASIL trial included patients with infrainguinal rather than isolated IP disease, it offers the most relevant data in this regard. The periprocedural mortality (5.5%), myocardial infarction (7%), stroke (1.5%), and surgical wound complication (22%) rates reported in this study13 are clearly higher than the expected rates for these outcomes with endovascular approaches.

Objective performance goals for patients with CLI have been developed from large clinical trial databases, and they define an important clinical outcome as the absence of 30-day mortality or major adverse limb events (amputation or reintervention).34 The primary efficacy endpoint was set at 76.9% and amputation-free survival at 76.5%. This type of analysis may be helpful to provide perspective for noncomparative, nonrandomized data from clinical trials. The OLIVE registry reported data describing risk-adjusted outcomes for endovascular procedures35 in Japanese patients with CLI. Heart failure, wound infections, and being underweight (body mass index < 18.5 kg/m2) increased the risk for a worse outcome and decreased amputation-free survival. Since the BASIL trial, there has been a widespread temporal adoption of an endovascular-first approach for CLI. Technical success rates approaching 100% have been reported, but these likely suffer from case selection and reporting bias. In a large meta-analysis of IP PTA as the primary treatment modality, the 3-year limb salvage rate was 82.4%36 compared to 82.3% with an open surgical approach.31

Currently, the BEST-CLI study is enrolling patients in an attempt to compare the best endovascular versus the best surgical approach to treat CLI. Enrollment has been slow, and most of the sites enrolling patients are centers with predominantly surgical expertise. We all hope for an equilibrated enrollment, which would truly allow us to compare which strategy is best; however, it seems intuitive that patients will be better served on an individual basis by the local expertise. We must remain tuned to these awaited results.

New Adjunctive Technologies

Several adjunctive endovascular devices, including atherectomy, cryoplasty, cutting balloons, and lasers, have shown safety and feasibility in the IP segment but have failed to show superiority when compared with PTA.20,37-39 The data quality is compromised, as they largely represent retrospective reports or uncontrolled registries (subject to selection bias) from individual centers.

Drug-Eluting Stents

After data from the BASIL trial were released, the preferred endovascular approach was PTA, with BMS reserved for preserving patency in case of dissection as a bailout technique. As drug-eluting stent (DES) platforms became established in the coronary bed, four RCTs tested DES in IP lesions. The ACHILLES trial randomized 200 patients with IP disease to PTA or DES (Cypher Select sirolimus-eluting stent, Cordis Corporation) and found superior patency rates at 1 year for DES (75% vs 57.1% for PTA; P = .025).40 There was no difference in terms of death, amputation rates, or improved clinical status. The DESTINY study randomized 140 patients with CLI and IP disease to BMS (Multi-Link Vision, Abbott Vascular) or DES (Xience V, Abbott Vascular).41 Over 12 months of follow-up, the DES group showed superior patency (DES 85% vs BMS 54%; P < .001) and freedom from reinterventions (DES 91% vs BMS 66%; P = .001). There was no difference in clinical Rutherford class improvement, major amputations, or mortality.

The YUKON-BTX trial randomized 161 patients to IP treatment with BMS or DES (Yukon sirolimus-eluting stent, Translumina) and found superior patency at 12 months for the DES group but no difference in event-free survival.42 The IDEAS RCT compared DCB versus DES in long (> 70 mm) IP lesions in patients with Rutherford categories 3 to 6. Restenosis was significantly lower in the DES group (28% vs 57.9%; P = .046). There were no differences in TLR rates.43 However, the preponderance of the evidence for IP DES use has demonstrated a significant benefit over both BMS and PTA in terms of patency, reduced reinterventions, reduced amputations, and improved event-free survival. These results are not specific to CLI, as most trials have included severe claudicants in their populations. It is also likely that the lesions selected for randomized trials do not reflect real-world IP lesions (ie, fewer lesions, more discrete lesions, less calcified lesions, and fewer occlusions). There are only limited clinical data available on the IP applications of DCBs.

A registry of 104 patients treated with IP PTA using a DCB (In.Pact Amphirion, Medtronic) demonstrated favorable results compared to historical controls for restenosis reduction, and there were no safety issues noted.44 The DEBATE-BTK trial randomized 132 diabetic patients with CLI and 158 IP lesions to either DCB (In.Pact Amphirion) or PTA.45 Notably, the mean lesion length was 129 ± 83 mm, which is dramatically longer (~100 mm) than lesions treated in the IP DES randomized trials. Restenosis (DCB 27% vs PTA 74.3%; P < .001), target vessel occlusion (DCB 17.6% vs PTA 55.4%; P < .001), and 1-year major adverse events (DCB 31% vs PTA 51%; P = .02) all favored DCBs. However, there was no difference in amputation, limb salvage, or mortality rates. The IN.PACT DEEP trial outcomes resulted in the withdrawal of the In.Pact Amphirion DCB from the worldwide market by the sponsor. The trial enrolled 358 CLI patients with IP lesions. Twelve-month late lumen loss and clinically driven TLR for those in the DCB group were not different from the control group, and there was a nonsignificant trend toward higher amputation rates in the DCB group.46 There are few adverse periprocedural events with endovascular therapy for the treatment of IP disease, with mortality rates in observational series approaching < 1%. Several mechanisms have been proposed to explain the lack of benefit in this study (compared to DEBATE-BTK), including the use of a balloon that was coated with a different technique and a balloon size that was an average of 0.5 mm smaller (by visual estimate) than those used by Liistro et al.45 The difference in balloon size has the potential to cause vessel-balloon mismatch, leading to a lack of contact between the balloon and the intima and therefore compromising the drug transfer to the media.

CONCLUSION

It appears evident that PTA results have reached their zenith, and adjunctive modalities deserve to be systematically studied in order to analyze their likely superior results. Appropriate study design can potentially shine a different light on outcomes of endovascular therapies for below-the-knee disease. There is a need for large-scale, multicenter, prospective studies with inclusion criteria that encompass real-world patients with CLI along with currently available and future disruptive technologies in order to generate relevant and generalizable data that can be used as the best source of evidenced-based standards to treat this complex disease.

Although challenging, the future of CLI treatment is exciting, with increasing focus on optimal wound care and prevention; adherence to proven medical therapies; improving revascularization results with novel techniques; devices and approaches; and, most definitely, with the establishment of CLI centers of excellence with dedicated multidisciplinary teams. A gap remains between real-world CLI practice and evidence-based therapies, which is fed by the disparity between real-world patients and those enrolled in clinical trials. The education of patients, physicians, health-allied personnel, institutions, politicians, industry, and all of the stakeholders is one of the missions of the recently created CLI Global Society (www.cliglobal.com), and its accomplishment will undoubtedly continue to narrow this gap. This society was founded with the purpose of bringing CLI to the forefront. Global experts carry the baton and will be responsible for creating awareness, guidelines, protocols, and tools that adapt to the reality of each individual country, as we understand the nuances introduced by the different cultures, politics, and socioeconomic realities.

1. Pande RL, Perlstein TS, Beckman JA, et al. Secondary prevention and mortality in peripheral artery disease: National Health and Nutrition Examination Study, 1999 to 2004. Circulation. 2011;124:17-23.

2. Smith GD, Shipley MJ, Rose G. Intermittent claudication, heart disease risk factors, and mortality. The Whitehall Study. Circulation. 1990;82:1925-1931.

3. Fowkes FG, Murray GD, Butcher I, et al. Ankle brachial index combined with Framingham Risk Score to predict cardiovascular events and mortality: a meta-analysis. JAMA. 2008;300:197-208.

4. Stoffers HE, Kester AD, Kaiser V, et al. The diagnostic value of the measurement of the ankle-brachial systolic pressure index in primary health care. J Clin Epidemiol. 1996;49:1401-1405.

5. Hirsch AT, Criqui MH, Treat-Jacobson D, et al. Peripheral arterial disease detection, awareness, and treatment in primary care. JAMA. 2001;286:1317-1324.

6. Jaff MR, White CJ, Hiatt WR, et al. An update on methods for revascularization and expansion of the TASC lesion classification to include below-the-knee arteries: a supplement to the Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). J Endovasc Ther. 2015;22:657-671.

7. Norgren L, Hiatt WR, Dormandy JA, et al. Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). Eur J Vasc Endovasc Surg. 2007;33(suppl 1):S1-75.

8. Feiring AJ, Krahn M, Nelson L, et al. Preventing leg amputations in critical limb ischemia with below-the-knee drug-eluting stents: the PARADISE (Preventing Amputations Using Drug Eluting Stents) trial. J Am Coll Cardiol. 2010;55:1580-1589.

9. Peacock JM, Keo HH, Duval S, et al. The incidence and health economic burden of ischemic amputation in Minnesota, 2005-2008. Prev Chronic Dis. 2011;8:A141.

10. Allie DE, Hebert CJ, Lirtzman MD, et al. Critical limb ischemia: a global epidemic.A critical analysis of current treatment unmasks the clinical and economic costs of CLI. EuroIntervention. 2005;1:75-84.

11. Goodney PP, Travis LL, Nallamothu BK, et al. Variation in the use of lower extremity vascular procedures for critical limb ischemia. Circ Cardiovasc Qual Outcomes. 2012;5:94-102.

12. Conte MS. Bypass Versus Angioplasty in Severe Ischaemia of the Leg (BASIL) and the (hoped for) dawn of evidence-based treatment for advanced limb ischemia. J Vasc Surg. 2010;51(5 suppl):69S-75S.

13. Adam DJ, Beard JD, Cleveland T, et al. Bypass versus angioplasty in severe ischaemia of the leg (BASIL): multicentre, randomised controlled trial. Lancet. 2005;366:1925-1934.

14. Jones WS, Dolor RJ, Hasselblad V, et al. Comparative effectiveness of endovascular and surgical revascularization for patients with peripheral artery disease and critical limb ischemia: systematic review of revascularization in critical limb ischemia. Am Heart J. 2014;167:489-498.e7.

15. Geraghty PJ, Mewissen MW, Jaff MR, et al. Three-year results of the VIBRANT trial of VIABAHN endoprosthesis versus bare nitinol stent implantation for complex superficial femoral artery occlusive disease. J Vasc Surg. 2013;58:386-395.e4.

16. Laird JR, Katzen BT, Scheinert D, et al. Nitinol stent implantation versus balloon angioplasty for lesions in the superficial femoral artery and proximal popliteal artery: twelve-month results from the RESILIENT randomized trial. Circ Cardiovasc Interv. 2010;3:267-276.

17. Laird JR, Katzen BT, Scheinert D, et al. Nitinol stent implantation vs. balloon angioplasty for lesions in the superficial femoral and proximal popliteal arteries of patients with claudication three-year follow-up from the RESILIENT randomized trial. J Endovasc Ther. 2012;19:1-9.

18. Brescia AA, Wickers BM, Correa JC, et al. Stenting of femoropopliteal lesions using interwoven nitinol stents. J Vasc Surg. 2015;61:1472-1478.

19. Das T, Mustapha J, Indes J, et al. Technique optimization of orbital atherectomy in calcified peripheral lesions of the lower extremities: the CONFIRM series, a prospective multicenter registry. Catheter Cardiovasc Interv. 2014;83:115-122.

20. Laird JR, Zeller T, Gray BH, et al. Limb salvage following laser-assisted angioplasty for critical limb ischemia: results of the LACI multicenter trial. J Endovasc Ther. 2006;13:1-11.

21. Zeller T, Krankenberg H, Steinkamp H, et al. One-year outcome of percutaneous rotational atherectomy with aspiration in infrainguinal peripheral arterial occlusive disease: the multicenter pathway PVD trial. J Endovasc Ther. 2009;16:653-662.

22. Zeller T, Rastan A, Sixt S, et al. Long-term results after directional atherectomy of femoro-popliteal lesions. J Am Coll Cardiol. 2006;48:1573-1578.

23. McKinsey JF, Zeller T, Rocha-Singh KJ, et al. Lower extremity revascularization using directional atherectomy: 12-month prospective results of the DEFINITIVE LE study. JACC Cardiovasc Interv. 2014;7:923-933.

24. Dake MD, Ansel GM, Jaff MR, et al. Sustained safety and effectiveness of paclitaxel-eluting stents for femoropopliteal lesions: 2-year follow-up from the Zilver PTX randomized and single-arm clinical studies. J Am Coll Cardiol. 2013;61:2417-2427.

25. Dake MD, Ansel GM, Jaff MR, et al. Durable clinical effectiveness with paclitaxel-eluting stents in the femoropopliteal artery: 5-year results of the Zilver PTX randomized trial. Circulation. 2016;133:1472-1483.

26. Tepe G, Laird J, Schneider P, et al. Drug-coated balloon versus standard percutaneous transluminal angioplasty for the treatment of superficial femoral and popliteal peripheral artery disease: 12-month results from the IN.PACT SFA randomized

trial. Circulation. 2015;131:495-502.

27. Rosenfield K, Jaff MR, White CJ, et al. Trial of a Paclitaxel-coated balloon for femoropopliteal disease. N Eng J Med. 2015;373:145-153.

28. Micari A, Vadala G, Castriota F, et al. 1-year results of paclitaxel-coated balloons for long femoropopliteal artery disease: evidence from the SFA-Long study. JACC Cardiovasc Interv. 2016;9:950-956.

29. Gray BH, Diaz-Sandoval LJ, Dieter RS, et al. SCAI expert consensus statement for infrapopliteal arterial intervention appropriate use. Catheter Cardiovasc Interv. 2014;84:539-545.

30. Albers M, Romiti M, Brochado-Neto FC, et al. Meta-analysis of alternate autologous vein bypass grafts to IP arteries. J Vasc Surg. 2005;42:449-455.

31. Albers M, Romiti M, Pereira CA, et al. Meta-analysis of allograft bypass grafting to IP arteries. Eur J Vasc Endovasc Surg. 2004;28:462-472.

32. Dorweiler B, Neufang A, Schmiedt W, et al. Pedal arterial bypass for limb salvage in patients with diabetes mellitus. Eur J Vasc Endovasc Surg. 2002;24:309-313.

33. Kashyap VS, Ahn SS, Quinones-Baldrich WJ, et al. Infrapopliteal-lower extremity revascularization with prosthetic conduit: a 20-year experience. Vasc Endovascular Surg. 2002;36:255-262.

34. Conte MS, Geraghty PJ, Bradbury AW, et al. Suggested objective performance goals and clinical trial design for evaluating catheter-based treatment of critical limb ischemia. J Vasc Surg. 2009;50:1462-1473.e1-3.

35. Iida O, Nakamura M, Yamauchi Y, et al. Endovascular treatment for infrainguinal vessels in patients with critical limb ischemia: OLIVE registry, a prospective, multicenter study in Japan with 12-month follow-up. Circ Cardiovasc Interv. 2013;6:68-76.

36. Romiti M, Albers M, Brochado-Neto FC, et al. Meta-analysis of infrapopliteal angioplasty for chronic critical limb ischemia. J Vasc Surg. 2008;47:975-981.

37. Ansel GM, Sample NS, Botti IC Jr, et al. Cutting balloon angioplasty of the popliteal and infrapopliteal vessels for symptomatic limb ischemia. Catheter Cardiovasc Interv. 2004;61:1-4.

38. Das T, McNamara T, Gray B, et al. Cryoplasty therapy for limb salvage in patients with critical limb ischemia. J Endovasc Ther. 2007;14:753-762.

39. Zeller T, Rastan A, Schwarzwalder U, et al. Midterm results after atherectomy-assisted angioplasty of below-knee arteries with use of the Silverhawk device. J Vasc Interv Radiol. 2004;15:1391-1397.

40. Scheinert D, Katsanos K, Zeller T, et al. A prospective randomized multicenter comparison of balloon angioplasty and infrapopliteal stenting with the sirolimus-eluting stent in patients with ischemic peripheral arterial disease: 1-year results from the ACHILLES trial. J Am Coll Cardiol. 2012;60:2290-2295.

41. Bosiers M, Scheinert D, Peeters P, et al. Randomized comparison of everolimus-eluting versus bare-metal stents in patients with critical limb ischemia and infrapopliteal arterial occlusive disease. J Vasc Surg. 2012;55:390-398.

42. Rastan A, Tepe G, Krankenberg H, et al. Sirolimus-eluting stents vs. bare-metal stents for treatment of focal lesions in infrapopliteal arteries: a double-blind, multi-centre, randomized clinical trial. Eur Heart J. 2011;32:2274-2281.

43. Siablis D, Kitrou PM, Spiliopoulos S, et al. Paclitaxel-coated balloon angioplasty versus drug-eluting stenting for the treatment of infrapopliteal long-segment arterial occlusive disease: the IDEAS randomized controlled trial. JACC Cardiovasc Interv. 2014;7:1048-1056.

44. Schmidt A, Piorkowski M, Werner M, et al. First experience with drug-eluting balloons in infrapopliteal arteries: restenosis rate and clinical outcome. J Am Coll Cardiol. 2011;58:1105-1109.

45. Liistro F, Porto I, Angioli P, et al. Drug-eluting balloon in peripheral intervention for below the knee angioplasty evaluation (DEBATE-BTK): a randomized trial in diabetic patients with critical limb ischemia. Circulation. 2013;128:615-621.

46. Zeller T, Baumgartner I, Scheinert D, et al. Drug-eluting balloon versus standard balloon angioplasty for infrapopliteal arterial revascularization in critical limb ischemia: 12-month results from the IN.PACT DEEP randomized trial. J Am Coll Cardiol. 2014;64:1568-1576.

Larry J. Diaz-Sandoval, MD
Interventional cardiologist
Metro Health Hospital
Wyoming, Michigan
Clinical Assistant Professor of Medicine
Michigan State University CHM and COM
East Lansing, Michigan
ldiazjr71@gmail.com
Disclosures: Consultant to Bard Peripheral Vascular.

J.A. Mustapha, MD
Director of Cardiovascular Catheterization
Laboratories
Metro Health Hospital
Wyoming, Michigan
Clinical Associate Professor of Medicine
Michigan State University CHM and COM
East Lansing, Michigan
jihad.mustapha@metrogr.org
Disclosures: Consultant to Bard Peripheral Vascular and Medtronic.

Fadi Saab, MD
Interventional cardiologist
Metro Health Hospital
Wyoming, Michigan
Clinical Assistant Professor of Medicine
Michigan State University CHM and COM
East Lansing, Michigan
Disclosures: Consultant to Bard Peripheral Vascular and Medtronic.